Biosergen
Biosergen publishes interim report for fourth quarter 2023
REG
Summary of the Interim Report for Q4 2023
| 2023 | 2022 | 2023 | 2022 | |
| TSEK | Oct-Dec | Oct-Dec | Jan-Dec | Jan-Dec |
| Other income | 1.315 | 1.964 | 9.378 | 5.183 |
| Profit/loss before depreciation (EBITDA) | -6.662 | -12.491 | -27.266 | -39.987 |
| Operating profit/loss befor net financials | -6.662 | -12.491 | -27.037 | -39.987 |
| Net financials | 193 | 87 | 229 | 109 |
| Netprofit/loss for the period | -6.469 | -12.432 | -27.037 | -39.906 |
| Earnings per share (SEK) | -0,13 | -0,40 | -0,53 | -1,28 |
Highlights during Q4 2023
- December 12, Biosergen’s Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy
Highlights after the period
- February 12, Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
- January 30, Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan
- January 12, Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor
The Financial report can be found on our website: https://biosergen.net/investors/filings
| Datum | 2024-02-29, kl 08:35 |
| Källa | Cision |
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet